Toralizumab

Names

[ Name ]:
Toralizumab

Biological Activity

[Description]:

Toralizumab (IDEC-131) is a humanized monoclonal antibody (mAb) against CD40L (CD154) comprised of human gamma 1 heavy chains and human kappa light chains. Toralizumab binds specifically to human CD40L on T cells, thereby preventing CD40 signaling. Toralizumab, a immunosuppressive drug, has the potential for active systemic lupus erythematosus (SLE) research[1][2].

[Related Catalog]:

Research Areas >> Inflammation/Immunology

[Target]

CD40L

[References]

[1]. Camilo E Fadul, et al. Safety and Immune Effects of Blocking CD40 Ligand in Multiple Sclerosis. Neurol Neuroimmunol Neuroinflamm. 2021 Oct 15;8(6):e1096.

[2]. Kenneth C Kalunian, et al. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002 Dec;46(12):3251-8.

Chemical & Physical Properties

[ Appearance of Characters ]:
lyophilized powder

[ Storage condition ]:
−20°C

Safety Information

[ Hazard Codes ]:
Xn

[ Risk Phrases ]:
22

[ WGK Germany ]:
3

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.